Compare CGNX & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | ALGN |
|---|---|---|
| Founded | 1981 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.7B |
| IPO Year | 1994 | 2000 |
| Metric | CGNX | ALGN |
|---|---|---|
| Price | $63.68 | $173.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $57.91 | ★ $199.82 |
| AVG Volume (30 Days) | ★ 1.9M | 871.9K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 9.68 | 0.53 |
| EPS | 0.74 | ★ 3.09 |
| Revenue | N/A | ★ $387,126,000.00 |
| Revenue This Year | $9.52 | $5.78 |
| Revenue Next Year | $8.63 | $4.62 |
| P/E Ratio | $90.39 | ★ $56.20 |
| Revenue Growth | N/A | ★ 23.95 |
| 52 Week Low | $34.60 | $122.00 |
| 52 Week High | $72.88 | $200.44 |
| Indicator | CGNX | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 49.55 |
| Support Level | $62.63 | $164.70 |
| Resistance Level | $70.53 | $176.17 |
| Average True Range (ATR) | 2.84 | 6.54 |
| MACD | 0.47 | 0.00 |
| Stochastic Oscillator | 52.61 | 37.50 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. Geographically, it operates in United states, Europe, Greater China and others. Cognex generates the maximum proportion of its sales in the United States and Europe.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.